AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 311 min read$DGX

PREVOZNIK MICHAEL E sold $5.5M of DGX

PREVOZNIK MICHAEL E (SVP & General Counsel) sold 22,677 shares of QUEST DIAGNOSTICS INC (DGX) at an average of $243.11 ($242.88–$244.51, $5.51M total) across 3 trades on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PREVOZNIK MICHAEL E
Published Aug 31, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DGX
Bearish
medium confidence
Mentioned
$DGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXBearishMed
01

Why it matters

The disclosed sale provides fresh data on insider sentiment and may influence short‑term price action.

02

Market read

First‑report insider sale of $5.5 M; relevant for traders monitoring DGX.

03

What to watch

Potential upcoming earnings release could offset the negative sentiment from the insider sale.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑08‑28

Background

SEC Form 4 filing discloses insider transaction for Quest Diagnostics (DGX).

Company-level read

Ticker impact

$DGXBearishMedium confidence
Context

SVP & General Counsel sold 22,677 shares for $5.5M via a 10b5‑1 plan

Expected impact

Possible short‑term dip as market digests the $5.5M sale.

Evidence & confidence

A senior officer off‑loading a sizable stake signals reduced confidence; however, the sale is pre‑arranged under a 10b5‑1 plan, limiting immediate informational value.

Market effects

Sector

Minimal impact on healthcare diagnostics sector; insider activity is company‑specific.

Regional

U.S. market only; no broader regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale may be purely portfolio rebalancing under a 10b5‑1 plan, not a bearish signal.

Key entities

  • Company
    Quest Diagnostics Inc.

    Issuer of the Form 4 filing.

  • Individual
    Michael E. Prevoznick

    SVP & General Counsel, insider seller.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DGX insider trading history →

Related articles

OCT 1
$DGXLow

Quest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in

Quest Diagnostics (DGX) reported high accuracy of its Haystack MRD test in detecting residual and recurrent disease in colorectal cancer and other solid tumors. The study showed 100% sensitivity and specificity at three years, and 83.3% sensitivity at five years. DGX is trading at $233.33, 18.5% above its GF Value™ of $196.83, indicating modest overvaluation.

gurufocus.com3 min
OCT 1
$DGXMed

Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

Quest Diagnostics' Haystack MRD® test showed 100% specificity and high sensitivity in detecting colorectal cancer recurrence, per a study in The Journal of Molecular Diagnostics. The test, using circulating tumor DNA, outperformed standard biomarkers and validated its performance across 23 solid tumor types. Quest Diagnostics is the provider of the test.

prnewswire.com2 min
SEP 22
$DGXHighAI 8/10

Why Quest Diagnostics Holdings Stock Dropped Today

Quest Diagnostics (DGX) stock fell 5.1% after CMS announced plans to cut lab reimbursement rates by up to 15% starting 2027, affecting 11% of Quest's 2025 revenue. The company had previously warned of such risks in its SEC filing. CMS estimates annual savings of $1 billion from the cuts.

fool.com2 min
SEP 22
$BABAMed

Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.

cnbc.com2 min
SEP 22
$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

investing.com2 min